Ventricular Arrhythmias in Patients Undergoing Mitral Valve Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Mitral valve surgery: Mitral valve repair or replacement of mitral regurgitation

Study summary

Study objectives:

* To assess the impact of mitral valve surgery for mitral regurgitation on ventricular arrhythmic burden and surrogate markers of fibrosis in patients with arrhytmogenic mitral valve prolapse (MVP) from baseline to 6 months after surgery
* To characterize the molecular landscape of arrhytmogenic MVP

Study design:

-Prospective explorative observational study

Study population:

-90 patients with arrhytmogenic MVP and without arrhytmogenic MVP (controls) eligible for mitral valve surgery for mitral regurgitation will be enrolled. All patients will be evaluated with cardiac magnetic resonance (CMR) imaging and continuous seven day arrhythmic monitoring before and at 6 months after mitral valve surgery

Eligibility

Primary outcome measure(s)

• Ventricular arrhythmias — 6 months
  Change in ventricular arrhythmic burden (composite of non-sustained or sustained ventricular tachycardias, ventricular fibrillation or premature ventricular complexes)
• Extracellular volume — 6 months
  Change in indexed extracellular volume as surrogate marker for diffuse reversible fibrosis measured by CMR

Trial sites (1)

More Karolinska Institutet trials in Sweden

Other trials for the same condition